Roche cobas HPV test shows promise in cervical cancer screening

20 September 2011 (Last Updated September 20th, 2011 18:30)

Roche's ATHENA study has demonstrated that human papillomavirus (HPV) DNA tests, including the Roche cobas HPV Test, provide an additional primary screening test for cervical cancer.

Roche's ATHENA study has demonstrated that human papillomavirus (HPV) DNA tests, including the Roche cobas HPV Test, provide an additional primary screening test for cervical cancer.

The cobas HPV test individually identifies genotypes 16 and 18, while simultaneously detecting 12 other high-risk HPV genotypes.
ATHENA data showed that identifying women with HPV 16 or 18, the two genotypes detected in approximately 70% of cervical cancers, provided important predictive information to determine a woman's risk of cervical disease.

The results from the study indicate that HPV testing with separate HPV 16 and HPV 18 detection could provide a sensitive and efficient strategy for cervical cancer screening than other methods.

University of Virginia Health System surgical pathology and cytopathology professor and associate director Mark Stoler said the new data suggests that HPV testing is an efficient, reliable and potentially cost-effective primary screening tool.

"Moreover, the use of the HPV 16 and 18 genotyping information provided by the cobas HPV Test or reflex cytology, would offer a rational approach for determining which HPV positive women need immediate follow up," Stoler added.